Cell4Pharma is a contract research organization that provides nephrotoxicity and drug‑drug interaction screening using its proprietary ciPTEC human renal proximal tubule cell lines, which stably express key kidney transporters. The service delivers high‑content, multi‑parametric assay data to help pharma, biotech, and academic researchers identify renal safety issues early and reduce reliance on animal testing.
Funding
Funding not disclosed
Founders
Product
Problem
Drug development programs often encounter late-stage failures due to unforeseen renal toxicity, leading to costly setbacks and reliance on animal testing that may not accurately predict human kidney responses.
Solution
Cell4Pharma offers a contract research service built around its proprietary ciPTEC human proximal tubule epithelial cell lines, which stably express key renal drug transporters. These cell lines proliferate indefinitely at permissive temperatures and differentiate to mimic in vivo kidney function at physiological temperature, enabling high‑content screening of nephrotoxicity and drug‑drug interaction potential. The platform provides quantitative readouts of transporter activity, biomarker expression, and cellular health, allowing early identification of compounds with adverse renal effects. By delivering predictive in vitro data, Cell4Pharma helps pharmaceutical, biotech, and academic researchers reduce reliance on animal studies and avoid late‑stage drug attrition.
Target Audience
Primary customers are pharmaceutical and biotechnology companies, contract research organizations, and academic research groups conducting preclinical ADME‑tox screening and renal safety assessments.
Features
- Stable human renal proximal tubule cell line (ciPTEC) with temperature‑controlled proliferation and differentiation
- Expression of major renal drug transporters (e.g., OAT1, OCT2) for active compound uptake and efflux
- High‑content, multi‑parametric assay workflow using fluorescent markers to assess toxicity, transporter activity, and biomarker changes
- Validated predictive performance for drug‑drug interactions and renal toxicity across a library of >60 reference compounds
- Compatibility with 3D perfused tubular structures (OrganoPlate) for enhanced physiological relevance
- Turnkey CRO service including assay design, execution, data analysis, and reporting